JP2014195454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014195454A5 JP2014195454A5 JP2014087047A JP2014087047A JP2014195454A5 JP 2014195454 A5 JP2014195454 A5 JP 2014195454A5 JP 2014087047 A JP2014087047 A JP 2014087047A JP 2014087047 A JP2014087047 A JP 2014087047A JP 2014195454 A5 JP2014195454 A5 JP 2014195454A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- receptor
- polypeptide
- protease
- hormone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 31
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 102000005962 receptors Human genes 0.000 claims 11
- 108020003175 receptors Proteins 0.000 claims 11
- 108091005804 Peptidases Proteins 0.000 claims 10
- 239000004365 Protease Substances 0.000 claims 10
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 10
- 210000004881 tumor cell Anatomy 0.000 claims 9
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 8
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 8
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 8
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 8
- 101710142969 Somatoliberin Proteins 0.000 claims 8
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 8
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 8
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims 8
- 208000010916 pituitary tumor Diseases 0.000 claims 8
- 230000005945 translocation Effects 0.000 claims 7
- 108010056088 Somatostatin Proteins 0.000 claims 6
- 231100000065 noncytotoxic Toxicity 0.000 claims 6
- 230000002020 noncytotoxic effect Effects 0.000 claims 6
- 108010055044 Tetanus Toxin Proteins 0.000 claims 5
- 102000005157 Somatostatin Human genes 0.000 claims 4
- 210000001163 endosome Anatomy 0.000 claims 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 4
- 229960000553 somatostatin Drugs 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108010051479 Bombesin Proteins 0.000 claims 2
- 108010073466 Bombesin Receptors Proteins 0.000 claims 2
- 101800001586 Ghrelin Proteins 0.000 claims 2
- 108010016122 Ghrelin Receptors Proteins 0.000 claims 2
- 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 claims 2
- 101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 claims 2
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 claims 2
- 101800002739 Melanin-concentrating hormone Proteins 0.000 claims 2
- 102400001132 Melanin-concentrating hormone Human genes 0.000 claims 2
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 claims 2
- 108010057464 Prolactin Proteins 0.000 claims 2
- 102000003946 Prolactin Human genes 0.000 claims 2
- 102000056271 Prolactin-releasing peptide receptors Human genes 0.000 claims 2
- 108700024163 Prolactin-releasing peptide receptors Proteins 0.000 claims 2
- 101150056450 UTS2R gene Proteins 0.000 claims 2
- 108010011107 Urotensins Proteins 0.000 claims 2
- 210000000172 cytosol Anatomy 0.000 claims 2
- 230000028023 exocytosis Effects 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 claims 2
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 239000000813 peptide hormone Substances 0.000 claims 2
- 229940097325 prolactin Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 102100028628 Bombesin receptor subtype-3 Human genes 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 102100034845 KiSS-1 receptor Human genes 0.000 claims 1
- 108010076800 Kisspeptin-1 Receptors Proteins 0.000 claims 1
- 101710138657 Neurotoxin Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000033052 Somatotropic adenoma Diseases 0.000 claims 1
- 102000012327 Urotensin II receptors Human genes 0.000 claims 1
- 108050002984 Urotensin II receptors Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000007375 bacterial translocation Effects 0.000 claims 1
- 108010063504 bombesin receptor subtype 3 Proteins 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000012202 endocytosis Effects 0.000 claims 1
- 208000020475 growth hormone-producing pituitary gland neoplasm Diseases 0.000 claims 1
- 201000010430 hormone producing pituitary cancer Diseases 0.000 claims 1
- 239000002581 neurotoxin Substances 0.000 claims 1
- 231100000618 neurotoxin Toxicity 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000007377 viral translocation Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0810782.3A GB0810782D0 (en) | 2008-06-12 | 2008-06-12 | Suppression of cancers |
| GB0810785.6 | 2008-06-12 | ||
| GB0810785A GB0810785D0 (en) | 2008-06-12 | 2008-06-12 | Suppression of neuroendocrine diseases |
| GB0810782.3 | 2008-06-12 | ||
| GB0820884.5 | 2008-11-14 | ||
| GB0820884A GB0820884D0 (en) | 2008-11-14 | 2008-11-14 | Suppression of neuroendocrine diseases |
| GB0820965.2 | 2008-11-17 | ||
| GB0820965A GB0820965D0 (en) | 2008-11-17 | 2008-11-17 | Suppression of cancers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513056A Division JP5728380B2 (ja) | 2008-06-12 | 2009-06-11 | 神経内分泌疾患の抑制 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014195454A JP2014195454A (ja) | 2014-10-16 |
| JP2014195454A5 true JP2014195454A5 (cg-RX-API-DMAC10.html) | 2014-11-27 |
| JP5891258B2 JP5891258B2 (ja) | 2016-03-22 |
Family
ID=41417177
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513056A Active JP5728380B2 (ja) | 2008-06-12 | 2009-06-11 | 神経内分泌疾患の抑制 |
| JP2014087047A Expired - Fee Related JP5891258B2 (ja) | 2008-06-12 | 2014-04-21 | 神経内分泌疾患の抑制 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513056A Active JP5728380B2 (ja) | 2008-06-12 | 2009-06-11 | 神経内分泌疾患の抑制 |
Country Status (12)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
| US10466245B2 (en) | 2008-02-20 | 2019-11-05 | The Secretary Of State For Health | Covalently linked thermostable kinase for decontamination process validation |
| GB0803068D0 (en) | 2008-02-20 | 2008-03-26 | Health Prot Agency | Cross-linked biological indicator |
| JP5728380B2 (ja) * | 2008-06-12 | 2015-06-03 | シンタクシン リミテッドＳｙｎｔａｘｉｎ Ｌｉｍｉｔｅｄ | 神経内分泌疾患の抑制 |
| GB0820970D0 (en) * | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
| GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| US10407730B2 (en) * | 2014-09-15 | 2019-09-10 | Clifton Life Sciences LLC | Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm |
| BR112017005598A2 (pt) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
| WO2016061583A1 (en) * | 2014-10-17 | 2016-04-21 | University Of Virginia Patent Foundation | Compositions and methods for treating pituitary tumors |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| TW201814045A (zh) | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
| CN109790204A (zh) | 2016-09-29 | 2019-05-21 | 益普生生物制药有限公司 | 杂合神经毒素 |
| EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| EP3375871A1 (en) * | 2017-03-13 | 2018-09-19 | SIT Biotech GmbH | Selective cell death-inducing enzyme system |
| AU2018275685B2 (en) * | 2017-05-31 | 2025-04-17 | Napo Pharmaceuticals, Inc. | Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome |
| BR112020006827A2 (pt) | 2018-01-29 | 2020-10-06 | Ipsen Biopharm Limited | neurotoxinas botulínicas clivando snare não neuronal |
| GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| CN110801512B (zh) * | 2019-11-15 | 2023-07-18 | 中国水产科学研究院黑龙江水产研究所 | 一种用于促进哲罗鲑性腺成熟的多肽及其应用 |
| CN111388651B (zh) * | 2020-05-09 | 2022-05-03 | 山东大学齐鲁医院 | Cst-14在制备骨质疏松症治疗药物中的应用 |
| CN113257370B (zh) * | 2021-05-12 | 2022-09-02 | 中国医学科学院北京协和医院 | 基于临床病理基本信息和vista检测的pnet复发风险预测模型 |
| WO2025155896A1 (en) * | 2024-01-19 | 2025-07-24 | Sling Therapeutics, Inc. | Use of inhibitors of insulin-like growth factor receptor-1 for growth hormone igf-secreting neoplasias |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291022A (en) | 1975-03-11 | 1981-09-22 | Sandoz Ltd. | Organic compounds |
| US4133782A (en) | 1976-06-07 | 1979-01-09 | The Salk Institute For Biological Studies | Somatostatin analogs with dissociated biological activities |
| US4190575A (en) | 1977-12-27 | 1980-02-26 | American Home Products Corporation | Polypeptides related to somatostatin |
| DE2860734D1 (en) | 1977-06-08 | 1981-09-03 | Merck & Co Inc | Somatostatin analogs, process for their preparation and pharmaceutical compositions containing them |
| US4211693A (en) | 1977-09-20 | 1980-07-08 | The Salk Institute For Biological Studies | Peptides with para-substituted phenylalanine |
| LU78191A1 (de) | 1977-09-28 | 1979-05-25 | Ciba Geigy Ag | Verfahren zur herstellung von neuen cyclopeptiden |
| JPS5819669B2 (ja) | 1978-10-28 | 1983-04-19 | 白井松新薬株式会社 | 新規生理活性ペプチド化合物及びその製造法 |
| US4190648A (en) | 1979-03-13 | 1980-02-26 | Merck & Co., Inc. | Peptides having somatostatin activity |
| US4316890A (en) | 1979-03-16 | 1982-02-23 | Ciba-Geigy Corporation | Peptides and processes for the manufacture thereof |
| US4328214A (en) | 1979-07-04 | 1982-05-04 | Ciba-Geigy Corporation | Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture |
| US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4369179A (en) | 1979-12-14 | 1983-01-18 | Ciba-Geigy Corporation | Acylpeptides |
| US4282143A (en) | 1980-06-13 | 1981-08-04 | American Home Products Corporation | Octapeptides lowering growth hormone |
| US4360516A (en) | 1981-04-13 | 1982-11-23 | Merck & Co., Inc. | Modified D-retro cyclic hexapeptide somatostatin analogs |
| DE3264693D1 (en) | 1981-12-24 | 1985-08-14 | Ciba Geigy Ag | Cyclic octapeptides and pharmaceutical compositions thereof, and processes for their production and use |
| FR2522655B1 (fr) | 1982-03-05 | 1987-03-06 | Sanofi Sa | Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant |
| US4522813A (en) | 1983-10-27 | 1985-06-11 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4659693A (en) | 1984-04-30 | 1987-04-21 | Syntex (U.S.A.) Inc. | N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides |
| US4632979A (en) | 1984-06-18 | 1986-12-30 | Tulane Educational Fund | Therapeutic LHRH analogs |
| US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| US5003011A (en) | 1985-04-09 | 1991-03-26 | The Administrators Of The Tulane Educational Fund | Therapeutic decapeptides |
| US4650787A (en) | 1985-04-25 | 1987-03-17 | Schally Andrew Victor | Biologically active octapeptides |
| US4725577A (en) | 1985-04-25 | 1988-02-16 | Administrators Of The Tulane Educational Fund | Biologically active lysine containing octapeptides |
| US4585755A (en) | 1985-04-29 | 1986-04-29 | Merck & Co., Inc. | Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents |
| US4904642A (en) | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4803261A (en) | 1986-06-27 | 1989-02-07 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide |
| HU206890B (en) | 1986-10-13 | 1993-01-28 | Sandoz Ag | Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components |
| US4871717A (en) | 1987-01-07 | 1989-10-03 | Administrators Of The Tulane Educational Fund | Peptides |
| WO1989002897A1 (en) | 1987-09-24 | 1989-04-06 | The Administrators Of The Tulane Educational Fund | Therapeutic peptides |
| US5084555A (en) | 1989-08-21 | 1992-01-28 | The Administrators Of The Tulane Educational Fund | An octapeptide bombesin analog |
| EP0329295A1 (en) | 1988-02-01 | 1989-08-23 | The Upjohn Company | Renin inhibiting peptides with polar end groups |
| NO893088L (no) | 1988-08-18 | 1990-02-19 | Syntex Inc | Fremgangsmaate for fremstilling av terapeutisk virksomme somatostatinlignende cykliske peptidforbindelser. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| JP2919889B2 (ja) | 1988-10-14 | 1999-07-19 | アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド | 治療用ペプチド |
| US5171835A (en) | 1988-10-21 | 1992-12-15 | The Administrators Of The Tulane Educational Fund | LHRH antagonists |
| CA2012115C (en) | 1989-03-15 | 2001-07-03 | Biomeasure, Inc. | Iodinated somatostatins |
| CA2053250A1 (en) | 1989-04-26 | 1990-10-27 | David H. Coy | Linear somatostatin analogs |
| WO1991009056A1 (en) | 1989-12-08 | 1991-06-27 | The Administrators Of The Tulane Educational Fund | Octapeptide analogs of somatostatin having threonine at the sixth position |
| ATE127476T1 (de) | 1990-04-06 | 1995-09-15 | Univ Tulane | Lhrh-analoge. |
| WO1991016923A1 (en) | 1990-05-04 | 1991-11-14 | The Administrators Of The Tulane University Educational Fund | Novel synthetic grf analogs |
| CA2081890A1 (en) | 1990-05-09 | 1991-11-10 | David H. Coy | Cyclized and linear therapeutic peptides |
| IT1240643B (it) | 1990-05-11 | 1993-12-17 | Mediolanum Farmaceutici Spa | Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| HU207104B (en) | 1991-01-25 | 1993-03-01 | Biosignal Kutato Fejlesztoe Kf | Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds |
| US6083915A (en) | 1991-05-10 | 2000-07-04 | Biomeasure, Inc. | Method for treating liver cancer |
| AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
| US5240561A (en) | 1992-02-10 | 1993-08-31 | Industrial Progress, Inc. | Acid-to-alkaline papermaking process |
| US5656727A (en) | 1992-09-15 | 1997-08-12 | The Administrators Of The Tulane Educational Fund | Antagonists of LHRH |
| AU5668894A (en) | 1992-11-13 | 1994-06-08 | The Administrators Of The Tulane Eductional Fund | Ghrh agonists |
| WO1994011397A1 (en) | 1992-11-13 | 1994-05-26 | The Administrators Of The Tulane Educational Fund | Ghrh agonists |
| GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| EP1288224B1 (en) | 1993-08-09 | 2008-06-25 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Therapeutic peptide derivatives |
| US5550212A (en) | 1993-12-17 | 1996-08-27 | The Administrators Of The Tulane Educational Fund | Analogues of hGH-RH(1-29)NH2 having antagonistic activity |
| AUPM985694A0 (en) | 1994-12-02 | 1995-01-05 | Farmer, Mostyn | Golf training aid |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| ATE170873T1 (de) | 1995-03-13 | 1998-09-15 | Biomeasure Inc | Bombesin-analogen |
| CA2218173A1 (en) | 1995-04-14 | 1996-10-17 | The Administrators Of The Tulane Educational Fund | Analogs of growth hormone-releasing factor |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| US5942489A (en) | 1996-05-03 | 1999-08-24 | The Administrators Of The Tulane Educational Fund | HGH-RH(1-29)NH2 analogues having antagonistic activity |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| WO1998008528A1 (en) | 1996-08-30 | 1998-03-05 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| US5968903A (en) | 1998-05-07 | 1999-10-19 | Biomeasure, Incorporated | Inhibition of H. pylori proliferation |
| KR100580541B1 (ko) | 1998-05-13 | 2006-05-16 | 비오테크콘 게젤샤프트 퓌어 비오테크놀로지셰 엔트리클룽 운트 콘술팅 엠베하 | 비만세포의 과립소실을 억제하기 위한 혼성 단백질 및 그사용방법 |
| WO2000004926A2 (en) | 1998-07-22 | 2000-02-03 | Osprey Pharmaceuticals Limited | Conjugates for treating inflammatory disorders and associated tissue damage |
| IL140837A0 (en) | 1998-07-30 | 2002-02-10 | Sod Conseils Rech Applic | Method of using lanreotide, a somatostatin analogue |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
| US6057422A (en) | 1998-11-25 | 2000-05-02 | The Administrators Of The Tulane Educational Fund | Antagonistic analogs of GH-RH inhibiting IGF-I and -II |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| CN1367793A (zh) | 1999-06-04 | 2002-09-04 | 研究及应用科学协会股份有限公司 | 神经调节肽b和生长抑素受体拮抗剂 |
| US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
| EP2267008B1 (en) * | 1999-08-25 | 2014-07-02 | Allergan, Inc. | Activatable recombinant neurotoxins |
| GB9922554D0 (en) * | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US20030180289A1 (en) * | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
| US7838008B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6827931B1 (en) * | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
| US6831059B2 (en) * | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
| WO2004076634A2 (en) * | 2003-02-24 | 2004-09-10 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease |
| TW200517400A (en) * | 2003-08-05 | 2005-06-01 | Univ Tulane | Antagonistic analogs of GH-RH (2003) |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| EP1982997B1 (en) * | 2004-09-01 | 2012-08-08 | Allergan, Inc. | Degradable clostridial toxins |
| CA2595115C (en) * | 2004-12-01 | 2014-01-21 | Health Protection Agency | Fusion proteins for treating, preventing or ameliorating pain |
| GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| EP1861419B1 (en) * | 2005-03-15 | 2011-06-29 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| DK2154151T3 (da) | 2005-09-19 | 2011-09-05 | Allergan Inc | Clostridiumtoksinaktiverbare clostridiumtoksiner |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| WO2008008805A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| AU2007272515B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| JP5728380B2 (ja) * | 2008-06-12 | 2015-06-03 | シンタクシン リミテッドＳｙｎｔａｘｉｎ Ｌｉｍｉｔｅｄ | 神経内分泌疾患の抑制 |
| BRPI0915142A8 (pt) * | 2008-06-12 | 2018-01-02 | Syntaxin Ltd | Polipeptídeos, ácido nucleico e usos dos mesmos |
| US10057187B1 (en) | 2015-05-27 | 2018-08-21 | Amazon Technologies, Inc. | Dynamic resource creation to connect client resources in a distributed system |
-
2009
- 2009-06-11 JP JP2011513056A patent/JP5728380B2/ja active Active
- 2009-06-11 BR BRC10915888A patent/BRPI0915888E2/pt not_active IP Right Cessation
- 2009-06-11 CN CN201410295607.7A patent/CN104328100B/zh not_active Expired - Fee Related
- 2009-06-11 EP EP09762018.1A patent/EP2310028B1/en active Active
- 2009-06-11 KR KR1020117000251A patent/KR101642363B1/ko not_active Expired - Fee Related
- 2009-06-11 ES ES13179177T patent/ES2750651T3/es active Active
- 2009-06-11 AU AU2009259033A patent/AU2009259033B2/en not_active Ceased
- 2009-06-11 WO PCT/GB2009/050665 patent/WO2009150469A2/en not_active Ceased
- 2009-06-11 EP EP19175007.4A patent/EP3590956A1/en active Pending
- 2009-06-11 CN CN200980130069.3A patent/CN102112145B/zh not_active Expired - Fee Related
- 2009-06-11 US US12/996,643 patent/US20110171191A1/en not_active Abandoned
- 2009-06-11 CA CA2727082A patent/CA2727082C/en not_active Expired - Fee Related
- 2009-06-11 EP EP13179177.4A patent/EP2719392B1/en active Active
- 2009-06-11 ES ES09762018.1T patent/ES2614990T3/es active Active
-
2010
- 2010-11-29 ZA ZA2010/08536A patent/ZA201008536B/en unknown
- 2010-12-08 IL IL209855A patent/IL209855A/en not_active IP Right Cessation
-
2014
- 2014-04-21 JP JP2014087047A patent/JP5891258B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2723774T3 (es) | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal | |
| NZ599259A (en) | Mycobacterial vaccines | |
| MX2022001134A (es) | Proteinas quimericas de factor viii y usos de estas. | |
| PE20190845A1 (es) | Metodos para determinar resistencia a terapia de receptor de androgeno | |
| MY184163A (en) | Transgene genetic tags and methods of use | |
| NZ745324A (en) | Vaccines and vaccine components for inhibition of microbial cells | |
| NZ702145A (en) | Bluetongue virus recombinant vaccines and uses thereof | |
| WO2009130618A3 (en) | Flagellin polypeptide vaccines | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| NZ628756A (en) | Immunogens for hiv vaccination | |
| ES2454773T3 (es) | Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN | |
| PH12012502428B1 (en) | Vaccine and methods to reduce campylobacter infection | |
| WO2016130628A8 (en) | Griffithsin mutants | |
| Zelena et al. | Escherichia coli as a production host for novel enzymes from basidiomycota | |
| WO2008151633A3 (en) | Vectors for vaccines against lentivirus infections | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| UA108778C2 (xx) | Протираковий злитий протеїн | |
| NZ629309A (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| EP4353256A3 (en) | Induction of cross-reactive cellular response against rhinovirus antigens | |
| NZ586074A (en) | LCLRP peptides, constructs and uses thereof | |
| MX2023002413A (es) | Proteinas de fusion inmunogenicas de coronavirus y metodos relacionados. | |
| TW201008576A (en) | New fusion proteins and their use for the preparation of vaccines against hepatitis C | |
| EP4717776A3 (en) | Polypeptide conjugates for intracellular delivery of nucleic acids | |
| WO2010040847A3 (en) | Recombinant protein bodies as immunogen-specific adjuvants | |
| HK1250992A1 (zh) | 表皮生长因子受体变体iii-间皮素融合物及其使用方法 |